Abstract
Backgroud: Tsutsugamushi disease was really uncommon in the pediatric clinical. However, it can be quite severe, those who suffer them Tsutsugamushi disease can progress to multiple organ dysfunction syndrome (MODS) and hemophagocytic syndrome (HPS). Unfortunately, there were few reports on pulmonary hemorrhage caused by tsutsugamushi disease, especially in children. Because of the nonspecific clinical presentations, it was difficult to differentiate from other diseases. The mortality would be up to 60% if inappropriate antibiotics were used.
Case Presentation: We report a three-year-old girl infected with tsutsugamushi, which manifested as MODS, HPS and diffuse alveolar hemorrhage. After administation of chloromycetin, the patient’s temperature fell down to normal 2 days later and mechanical ventilation was stopped after 1 week. The patient was discharged after three weeks of treatment. Since the typical eschar of tsutsugamushi disease is mostly concealed, misdiagnosis and delay in treatment often cause severe complications.
Conclusion: Chloromycetin may be an alternative antibiotic choice of treatment for severe pediatric tsutsugamushi disease, though it has toxic effects on bone marrow hematopoietic function.
Keywords: Chloromycetin, pediatric, pulmonary hemorrhage, tsutsugamushi.
Current Signal Transduction Therapy
Title:Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin
Volume: 10 Issue: 1
Author(s): Yafeng Liang, Linxia Wang, Xiaojiao Ye, Min Wang, Chunxue Yan and Guoquan Pan
Affiliation:
Keywords: Chloromycetin, pediatric, pulmonary hemorrhage, tsutsugamushi.
Abstract: Backgroud: Tsutsugamushi disease was really uncommon in the pediatric clinical. However, it can be quite severe, those who suffer them Tsutsugamushi disease can progress to multiple organ dysfunction syndrome (MODS) and hemophagocytic syndrome (HPS). Unfortunately, there were few reports on pulmonary hemorrhage caused by tsutsugamushi disease, especially in children. Because of the nonspecific clinical presentations, it was difficult to differentiate from other diseases. The mortality would be up to 60% if inappropriate antibiotics were used.
Case Presentation: We report a three-year-old girl infected with tsutsugamushi, which manifested as MODS, HPS and diffuse alveolar hemorrhage. After administation of chloromycetin, the patient’s temperature fell down to normal 2 days later and mechanical ventilation was stopped after 1 week. The patient was discharged after three weeks of treatment. Since the typical eschar of tsutsugamushi disease is mostly concealed, misdiagnosis and delay in treatment often cause severe complications.
Conclusion: Chloromycetin may be an alternative antibiotic choice of treatment for severe pediatric tsutsugamushi disease, though it has toxic effects on bone marrow hematopoietic function.
Export Options
About this article
Cite this article as:
Liang Yafeng, Wang Linxia, Ye Xiaojiao, Wang Min, Yan Chunxue and Pan Guoquan, Successful Treatment of Pulmonary Hemorrhage Associated with Pediatric Tsutsugamushi Disease by Chloromycetin, Current Signal Transduction Therapy 2015; 10 (1) . https://dx.doi.org/10.2174/1574362410666150311001316
DOI https://dx.doi.org/10.2174/1574362410666150311001316 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clozapine Induced Eosinophilia in a Case of Schizoaffective Disorder
Current Psychopharmacology Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Clinical Characteristics of Behcet’s Disease in 453 Egyptian Patients Suffering from Uveitis with Gender Comparison
Current Rheumatology Reviews Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews CD93 and Related Family Members: Their Role in Innate Immunity
Current Drug Targets Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Pathogenesis of Central Nervous System Tuberculosis
Current Molecular Medicine Subject Index to Volume 10
Current Pharmaceutical Design Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Resident Kidney Cells and Their Involvement in Glomerulonephritis
Current Drug Targets - Inflammation & Allergy Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Autonomic Nervous System Dysfunction in Sjogrens Syndrome
Current Rheumatology Reviews The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design